Zanubrutinib after CAR-T for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether taking a daily pill called zanubrutinib after CAR-T cell therapy can help keep your lymphoma from coming back. If you have non-Hodgkin B-cell lymphoma and you are about to start or are already taking zanubrutinib after CAR-T treatment, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your doctor has confirmed you have non-Hodgkin B-cell lymphoma.
- You have already had or are about to have CAR-T cell therapy, and you will take zanubrutinib pills afterward.
- Your platelet count is 50 or higher on a lab test.
- You are expected to live at least 12 weeks.
- You can understand the study and agree to follow its rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
This trial tests whether a drug called pirtobrutinib can help keep your lymphoma under control after you've received CAR-T cell therapy (a type of immune cell treatment). The study wants to see if adding this maintenance drug prevents the lymphoma from coming back.
This study tests a new way to prepare for CAR-T cell therapy for people with aggressive B-cell lymphoma who cannot have a stem cell transplant. Instead of using strong chemotherapy before CAR-T, this trial uses a pill-based regimen to keep the cancer under control and help the CAR-T cells work better.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.